New guidelines for the management of heart failure and AF

Researchers have welcomed recommendations for use of SGLT2 inhibitors in patients with type 2 diabetes, CVD risk, and insufficient glycaemic control despite metformin The National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand have published two sets of new guidelines: Guidelines for the Prevention, Detection, and Management of Heart Failure in